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Many southern African countries have undergone rapid demo­
graphic changes over the past decades, mainly attributable to 
urbanisation. [1] This demographic shift has led to a rise in non­
communicable diseases against the background of a high prevalence 
of HIV infection and an alarming incidence of tuberculosis.[2] 
The concept of ‘colliding epidemics’ is of particular importance in 
South Africa (SA), where we are faced with several major epidemics 
including HIV, tuberculosis and chronic obstructive pulmonary 
disease (COPD), both from cigarette smoking and from pollution, all 
of which may impact significantly on respiratory health.[3,4]
Lack of access to appropriate surveillance tools such as spirometry 
poses a major barrier to diagnosis and appropriate treatment in 
patients with chronic respiratory ailments such as COPD and 
asthma in poorly resourced countries. Despite the high prevalence 
in the general population, obstructive airway diseases continue to be 
underdiagnosed.[5,6]
Formal spirometry forms an integral part of the diagnosis and 
management of patients with asthma and COPD and relies on a 
competent operator, accurate equipment, standardised operating 
procedures, quality control and patient co­operation as outlined in 
the South African guideline for office spirometry.[7]
Mobile phone­linked spirometry technology has been designed 
specifically for evaluating lung function at primary care level, 
allowing patients access to potential diagnosis, monitoring and 
treatment in ways that are currently not available in these settings.
Several mobile spirometers have been developed over the years, 
most of which have several limitations, including not displaying a 
flow/volume loop.[8­12] The Air­Smart Spirometer with a loop display 
is the first mobile spirometer accepted in Europe for the cost­effective 
screening of patients with chronic respiratory diseases.[13]
Objectives
To prospectively assess the accuracy of the Air­Smart Spirometer 
to measure forced expiratory volume in the first second (FEV1) and 
forced vital capacity (FVC) in an SA population, and to investigate 
the ability of the device to reflect obstructive ventilatory impairment.
Methods
We conducted a prospective observational study at Tygerberg 
Hospital, Cape Town, SA, in which 200 consecutive patients and 
healthy volunteers were invited to participate. The study was approved 
by the Health Research Ethics Committee of Stellenbosch University 
(ref. no. S18/02/034). Participants were randomly (1:1) assigned 
to spirometry either with the mobile spirometer connected to a 
smartphone or the desktop spirometer first, followed by the other. 
Pulmonary function tests were performed in accordance with the 
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agreement between the two devices. We defined obstructive ventilatory impairment as FEV1/FVC <0.7 measured by desktop spirometry in 
order to calculate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the Air­Smart Spirometer.
Results. There was a strong correlation between the absolute FEV1 and FVC values and FEV1/FVC ratio measured with the mobile Air­
Smart Spirometer and more conventional pulmonary function testing, with r=0.951, r=0.955 and r=0.898, respectively. The Air­Smart 
Spirometer had a sensitivity of 97.6%, specificity of 74.4%, PPV of 73.0% and NPV of 97.8% for obstructive ventilatory impairment.
Conclusions. The mobile Air­Smart Spirometer compared well with conventional spirometry, making it an attractive and potentially affordable 
tool for screening purposes in a primary care setting. Moreover, it had a high sensitivity and NPV for obstructive ventilatory impairment.
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current American Thoracic Society, European Respiratory Society 
and South African Thoracic Society guidelines.[7,13] Desktop FEV1 and 
FVC were measured with a Jaeger Master Screen (Becton Dickinson, 
USA), which was calibrated daily, and mobile spirometry was done 
with the Air­Smart Spirometer (Pond Health Care Innovations, 
Sweden) (Fig. 1) connected to a smartphone following on­screen 
prompts in accordance with the manufacturer’s specifications.[14] The 
device has a turbine mechanism to perform measurements inside 
the disposable single­use nozzles. It does not require calibration, but 
parameters of age, sex and height are entered prior to spirometry.[14] 
To perform spirometry, participants were asked to perform forced 
exhalation of air into the turbine. This air turns a motor, and the 
device registers the speed of the rotor and in turn transfers the data 
to the smartphone application. When the patient initiates exhalation, 
a chronometer switches on and changes its colour from red to green 
after 6 seconds of exhalation.[14]
Comorbidities and demographic data (sex, age, height, weight and 
self­reported ethnicity) of the participants were documented. We 
subsequently compared the FEV1/FVC ratio as well as the absolute 
FEV1 and FVC measurements, using each participant as their own 
control. Data analysis was performed using SPSS statistics, version 
25 (IBM, USA). We considered a p­value <0.05 to be statistically 
signifi cant. We did a Pearson correlation analysis to assess the 
strength of the linear relationship between the devices, but since 
correlation analysis does not detect bias, we conducted a Bland­
Altman analysis[15] on all components of spirometry to assess the 
bias limits of agreement. We defined obstructive lung disease as an 
FEV1/FVC ratio <0.7 as measured by desktop spirometry in order to 
calculate the sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV) of the Air­Smart Spirometer.
Results
Comorbidities in the 200 participants (mean (standard deviation, 
SD) age 42.2 (21.3) years, n=83 males) included asthma (n=74), 
COPD (n=30), post­tuberculosis structural lung disease (n=18), 
bronchiectasis (n=14), lung masses (n=12), sarcoidosis (n=11), 
tuberculosis (n=6), interstitial lung disease (n=5), pulmonary 
hypertension (n=3), pleural effusions (n=3), pneumoconiosis (n=3) 
and previous pneumonectomy (n=2). Participants reported their race 
as mixed (n=140), white (n=41) and black African (n=19).
There was a strong correlation between the FEV1 measured with 
the devices, with r=0.951. (Fig. 2). The mean bias between the two 
devices was very close to 0 and not statistically significantly different 
from 0 (p=0.969). The 95% limits of agreement for the difference in 
FEV1 on the Bland­Altman plot (Fig. 3) were –35 mL to +35 mL. 
The plot shows a random distribution of the differences between 
the two devices with no specific pattern according to the mean of 
both devices and therefore no proportional bias present (β=–0.018, 
p=0.252).
For FVC we also observed a strong correlation, with r=0.955 
(Fig.  4). The mean bias was –0.128 L, which was significantly 
different from 0 (p<0.001). The Bland­Altman plot (Fig. 5) displayed 
a random distribution with the limits of agreement calculated 
at –70  mL to +45 mL. There was a significant proportional bias 
(β=– 0.045, p=0.039), which can be observed in Fig. 5 as a regression 
line that has a slight negative slope indicating that as the mean of the 
two devices increased, the differences became more negative.
The FEV1/FVC ratio measured with the Air­Smart Spirometer 
showed a strong correlation with the ratios obtained from standard 
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Fig. 2. Scatter plot of the FEV1 absolute values measured in the participants 
(N=200) with the Pearson correlation coefficient (r=0.951). (FEV1 = forced 
expiratory volume in the first second.)
Fig. 1. The Air-Smart Spirometer (Pond Health Care Innovations, Sweden), 
connected to a standard smartphone.
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Fig. 3. Bland-Altman plot comparing the two measurement techniques for 
absolute FEV1 values (N=200) (r=0.007). (FEV1 = forced expiratory volume 
in the first second.)
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spirometry, with r=0.898. The Air­Smart Spirometer had a sensitivity 
of 97.6% (95% confidence interval (CI) 90.8 ­ 99.6), specificity of 
74.4% (95% CI 65.3 ­ 81.8), PPV of 73.0% (95% CI 63.6 ­ 80.8) 
and NPV of 97.8% (95% CI 91.4 ­ 99.6) for obstructive ventilatory 
impairment.
Discussion
We found a strong correlation between the absolute FEV1 and 
FVC values and the FEV1/FVC ratio measured with the Air­Smart 
Spirometer and conventional pulmonary function testing, with 
r=0.951, r=0.955 and r=0.898, respectively. Moreover, Bland­Altman 
analysis showed that while for FEV1 there was minimal bias, for FVC 
the bias was larger and statistically significantly different from 0, but 
not clinically significant, as differences of <100 mL are generally not 
considered significant. The Air­Smart Spirometer had a sensitivity 
of 97.6%, specificity of 74.4%, PPV of 73.0% and NPV of 97.8% for 
obstructive ventilatory impairment.
In a recent study by Ramos Hernández et al.,[14] the utility of 
the Air­Smart Spirometer device to detect obstructive ventilatory 
impairment was tested in 200 patients (mean (SD) age 57 (14) years). 
Obstruction was detected by conventional spirometry in 73 patients 
(40.1%). Using an FEV1/FVC ratio <0.7 to detect obstruction with the 
Air­Smart Spirometer, the sensitivity was 90.4%, specificity 97.2%, 
PPV 95.7% and NPV 93.7% (compared with formal spirometry as 
the gold standard). The authors concluded that the device is simple, 
easy to use and accurate in detecting obstructive airway diseases.[14] 
We observed a comparable sensitivity and NPV (making it an ideal 
screening test), but lower specificity and PPV.
We believe that our results have major implications for a 
resource­constrained healthcare system servicing a vast population, 
including rural areas. Many parts of Africa have poor accessibility 
to spirometers, and even when they are available, expertise in their 
proper maintenance, calibration, technical aspects and interpretation 
is limited. Mobile devices connected to smartphones or other devices 
may be a revolutionary advance in the early detection and screening 
of chronic pulmonary disorders in primary healthcare settings, and 
the onscreen prompts should enable nurses and other primary care 
providers to perform the tests with limited training. The linked 
smartphone also allows for data to be analysed off site, and despite 
some limitations may eventually aid in the better understanding of 
appropriate reference values in black African patients, which are 
currently lacking.[7,16] Moreover, it may streamline referral to tertiary 
centres with limited capacity.
Study limitations
Our study has some limitations, including the facts that both sets of 
tests were performed by qualified pulmonary function technologists 
and that our study population included a relatively small number of 
black African patients. Future studies should focus on inexperienced 
personnel, and what the impact on accuracy (if any) may be should 
the mobile Air­Smart Spirometer be used in a primary healthcare 
setting.
Conclusions
The mobile Air­Smart Spirometer compared well with more 
conven tional spirometry, making it an attractive and potentially 
affordable tool for screening purposes in a primary care setting. 
Moreover, it has a high sensitivity and NPV for obstructive ventila­
tory impairment.
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(N=200) with the Pearson correlation coefficient (r=0.955). (FVC = forced 
vital capacity.)
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